ArticleStress biology2026
An NLR-VOZ seesaw: from asymmetric selection to synthetic broad-spectrum resistance.
Article in Stress biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A recent study in Nature identified the rice (Oryza sativa) nucleotide-binding site and leucine-rich repeat (NLR) receptor XA48, which recognized the ancient bacterial effector XopG and triggered immunity by promoting degradation of the negative regulators OsVOZ1/2. Population genomics revealed an asymmetric selection, with Xa48 retained in indica but lost in japonica due to a reproductive penalty. By stacking XA48-mediated effector-triggered immunity (ETI) with XA21-mediated pattern-triggered immunity (PTI) and introducing the compatible OsVOZ1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.